Page 8 - Binding Affinity News Today

A new review published in sums up the position of Omicron as a potential threat to human health, especially in the context of controlling this pandemic.

A new study compares the SARS-CoV-2 RBD to the SARS-CoV RBD using computational methods to understand their binding affinities to ACE2.

A new study presented a safe and efficient multi-epitope SARS-CoV-2 vaccine construct against SARS-CoV-2 variants, including Omicron.

In a recent study published in the journal PLOS Genetics, researchers explored severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) ribonucleic acid (RNA) editing in host cells.

Researchers discuss the evolution and mechanisms of mutations that have occurred in the spike protein of SARS-CoV-2.

A team of international scientists has recently isolated and characterized pan-coronavirus neutralizing antibodies from individuals with pre-existing immunity against SARS-CoV-2.

Researchers evaluated the ability of RBD antibodies to bind to and neutralize SARS-CoV-2 Omicron variant.

Researchers used a CNN regression model to investigate the effect of mutations on the binding affinity of the SARS-CoV-2 RBD-ACE2 complex.

Researchers investigated the impact of mutations in the SARS-CoV-2 variants of interest and variants of concern on the properties of the cluster of differentiation 8 T lymphocytes.

Researchers presented a systematic analysis of the affinity and conformational dynamics between the binding of SARS-CoV-2 receptor-binding domain spike protein and the host angiotensin-converting enzyme 2 receptor.